ChemBioChem · 2020 · 11 citations · 27 references
PharmacyOncologyPharmaceuticsDrug DeliveryDrug DesignDrug DiscoveryBispecific AntibodiesBispecific Antibody TherapyImmunogenicity Of Therapeutic AntibodiesTargeted Cancer TherapyTargeted TherapyTherapeutic Monoclonal AntibodiesAntibodiesAntitumor Immune ActivationBispecific Antibody DiscoveryFc-based Bispecific AntibodiesProstate Cancer ImmunotherapyProstate-specific Membrane Antigen TargetingTargeted Immune ActivationTumor-associated Antigen Targeting
Synthetic small molecules that redirect endogenous antibodies to target cells are promising drug candidates because they overcome the potential shortcomings of therapeutic antibodies, such as immunogenicity and the need for intravenous delivery. Previously, we reported a novel class of bispecific molecules targeting the antibody Fc region and folate receptor, named Fc-binding antibody-recruiting molecules (Fc-ARMs). Fc-ARMs can theoretically recruit most endogenous antibodies, inducing antibody-dependent cell-mediated cytotoxicity (ADCC) to eliminate cancer cells. Herein, we describe new Fc-ARMs that target prostate cancer (Fc-ARM-Ps). Fc-ARM-Ps recruited antibodies to cancer cells expressing prostate-specific membrane antigen but did so with lower efficiency compared with Fc-ARMs targeting the folate receptor. Upon recruitment by Fc-ARM-P, defucosylated antibodies efficiently activated natural killer cells and induced ADCC, whereas antibodies with intact N-glycans did not. The results suggest that the affinity between recruited antibodies and CD16a, a type of Fc receptor expressed on immune cells, could be a key factor controlling immune activation in the Fc-ARM strategy.
27
Structural basis for molecular recognition of folic acid by folate receptors
Chen Chen, Jiyuan Ke, X. Edward Zhou et al. · Nature · 2013 · 685 citations · Full text
G. M. Bartelds, Carla A. Wijbrandts, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2007 · 567 citations · Full text
Precision glycocalyx editing as a strategy for cancer immunotherapy
Han Xiao, Elliot C. Woods, Petar Vukojicic et al. · Proceedings of the National Academy of Sciences · 2016 · 444 citations · Full text
Medicine, Immunology, Oncology +17